ENDPOINTS

Regeneron loses bid to fend off false claims fight over Eylea

Regeneron can’t dodge a lawsuit alleging it unlawfully inflated Medicare reimbursements for its eye drug Eylea and defrauded the US out of hundreds of millions of dollars. On Tuesday, a federal judge in Massachusetts ...

Apr 30, 2025 - 18:43
 0
Regeneron loses bid to fend off false claims fight over Eylea
Regeneron can’t dodge a lawsuit alleging it unlawfully inflated Medicare reimbursements for its eye drug Eylea and defrauded the US out of hundreds of millions of dollars. On Tuesday, a federal judge in Massachusetts ...
Read More

Tags:

Previous Article

Food allergy discovery could pave way for new treatments

Next Article

Commure, HealthTap partner for expanded after-hours care

Related Posts

China’s biotech market is staging a comeback that US biotech can only wish for

China’s biotech market is staging a comeback that US bi...

Apr 23, 2025  0

Eli Lilly sues four telehealth companies selling compounded tirzepatide

Eli Lilly sues four telehealth companies selling compou...

Apr 23, 2025  0

Exclusive: Chicago startup Grove Biopharma nabs $30M Series A

Exclusive: Chicago startup Grove Biopharma nabs $30M Se...

Apr 23, 2025  0